VENTOLIN ROTACAPS Drug Patent Profile

Which patents cover Ventolin Rotacaps, and when can generic versions of Ventolin Rotacaps launch?

Ventolin Rotacaps is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in VENTOLIN ROTACAPS is albuterol sulfate. There are thirty-eight drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the albuterol sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ventolin Rotacaps

A generic version of VENTOLIN ROTACAPS was approved as albuterol sulfate by SUN PHARM INDUSTRIES on December 5^th, 1989.

Summary for VENTOLIN ROTACAPS

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	81
Patent Applications:	5,671
DailyMed Link:	VENTOLIN ROTACAPS at DailyMed

US Patents and Regulatory Information for VENTOLIN ROTACAPS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	VENTOLIN ROTACAPS	albuterol sulfate	CAPSULE;INHALATION	019489-001	May 4, 1988		DISCN	No	No

Expired US Patents for VENTOLIN ROTACAPS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	VENTOLIN ROTACAPS	albuterol sulfate	CAPSULE;INHALATION	019489-001	May 4, 1988	3,644,353
Glaxosmithkline	VENTOLIN ROTACAPS	albuterol sulfate	CAPSULE;INHALATION	019489-001	May 4, 1988	3,705,233

International Patents for VENTOLIN ROTACAPS

See the table below for patents covering VENTOLIN ROTACAPS around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	1643224
Cyprus	806	PHENYLAMINOETHANOL DERIVATIVES
Belgium	752892

VENTOLIN ROTACAPS Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for VENTOLIN ROTACAPS

Introduction to VENTOLIN ROTACAPS

VENTOLIN ROTACAPS, containing salbutamol (also known as albuterol in some regions), is a widely used medication for the treatment and prevention of bronchospasm associated with asthma and other respiratory conditions. It is a selective beta2-adrenoceptor agonist available in various formulations, including rotacaps, inhalers, and nebulizers.

Indications and Uses

VENTOLIN ROTACAPS are indicated for the relief of acute bronchospasm, prevention of allergen or exercise-induced bronchospasm, and chronic therapy for patients with asthma and other respiratory diseases. It is crucial for managing symptoms such as wheezing, difficulty breathing, chest tightness, and coughing caused by lung diseases like asthma and chronic obstructive pulmonary disease (COPD)[1].

Market Drivers

Increasing Prevalence of Respiratory Diseases

The global prevalence of respiratory diseases such as asthma, COPD, and bronchitis is on the rise, creating a significant demand for medications like VENTOLIN ROTACAPS. This increasing patient population drives the market growth as more individuals require effective management of their respiratory conditions[3].

Growing Awareness and Diagnosis

Improved awareness and diagnostic techniques have led to earlier detection and better management of respiratory diseases. This increased diagnosis rate contributes to the growing demand for albuterol-based medications[3].

Lifestyle Changes

Modern lifestyles, characterized by sedentary habits, poor dietary choices, and exposure to environmental pollutants, exacerbate respiratory diseases. Factors such as smoking, occupational hazards, and urbanization increase the risk of these conditions, further boosting the demand for VENTOLIN ROTACAPS[3].

Government Initiatives and Healthcare Expenditure

Governments and healthcare organizations are actively involved in addressing the burden of respiratory diseases through awareness campaigns, research support, and healthcare budget allocations. These initiatives enhance access to medications like VENTOLIN ROTACAPS, driving market growth[3].

Market Opportunities

Combination Therapies

Combination therapies that include albuterol along with other respiratory medications, such as corticosteroids or long-acting bronchodilators, offer significant market opportunities. These therapies provide enhanced efficacy and convenience, catering to the evolving needs of healthcare providers and patients[3].

Sustainability Initiatives

GSK's advancement of a low-carbon version of VENTOLIN using next-generation propellant technology is a major step towards sustainability. This initiative has the potential to reduce greenhouse gas emissions by approximately 90%, which could attract environmentally conscious consumers and regulatory support, further driving market growth[5].

Financial Trajectory

Current Market Size

The global albuterol market, which includes VENTOLIN ROTACAPS, was valued at USD 4587.68 million in 2022. This market is expected to grow to USD 7984.37 million by 2030, with a compound annual growth rate (CAGR) of 6.80% during the forecast period[3].

Revenue Growth

The increasing demand for albuterol due to the rising prevalence of respiratory diseases and improved diagnosis rates is expected to drive revenue growth. Additionally, the expansion of VENTOLIN ROTACAPS into new markets and the registration of these products in additional countries will contribute to this growth[2][3].

Cost Efficiencies and Pricing Strategies

GSK's efforts to offer incremental cost efficiencies and equitable pricing strategies, especially in middle-income countries, have enabled the company to increase the number of treated patients. For example, in Egypt, differentiated products within the respiratory portfolio have been offered to mirror income levels, doubling the number of treated patients over the last five years[2].

Distribution and Access

Global Registration and Distribution

VENTOLIN ROTACAPS have been registered in multiple countries, including recent registrations in three additional countries in 2016. This expanded reach supports better access to this critical medication globally[2].

Equitable Pricing

GSK's commitment to equitable pricing, particularly in middle-income countries, ensures that the medication is accessible to a broader segment of the population. This approach has been successful in increasing the number of patients treated and is expected to continue driving market growth[2].

Challenges and Special Precautions

Increasing Use of Short-Acting Beta-Agonists

The increasing use of short-acting inhaled beta-agonists like VENTOLIN ROTACAPS can indicate deteriorating asthma control. This necessitates a reassessment of the patient's therapy plan and potential concomitant glucocorticosteroid therapy[1].

Contraindications and Adverse Effects

VENTOLIN ROTACAPS are contraindicated in patients with severe milk-protein allergy or hypersensitivity to salbutamol or its formulation components. High therapeutic doses or overdoses can lead to adverse effects such as lactic acidosis and metabolic acidosis, requiring careful monitoring[1].

Key Takeaways

• The global albuterol market, including VENTOLIN ROTACAPS, is driven by the increasing prevalence of respiratory diseases and improved diagnosis rates.
• Combination therapies and sustainability initiatives offer significant market opportunities.
• Equitable pricing strategies and expanded global registration enhance access to the medication.
• Careful monitoring is required due to potential adverse effects and contraindications.

FAQs

What is VENTOLIN ROTACAPS used for?

VENTOLIN ROTACAPS are used for the treatment or prevention of bronchospasm associated with asthma and other respiratory conditions.

How does the increasing prevalence of respiratory diseases impact the market for VENTOLIN ROTACAPS?

The rising prevalence of respiratory diseases such as asthma and COPD increases the demand for medications like VENTOLIN ROTACAPS, driving market growth.

What are the potential adverse effects of using VENTOLIN ROTACAPS?

High therapeutic doses or overdoses of VENTOLIN ROTACAPS can lead to adverse effects such as lactic acidosis and metabolic acidosis.

How is GSK addressing sustainability concerns related to VENTOLIN?

GSK is advancing a low-carbon version of VENTOLIN using next-generation propellant technology, which has the potential to reduce greenhouse gas emissions by approximately 90%.

What is the expected market size of the albuterol market by 2030?

The global albuterol market is expected to reach USD 7984.37 million by 2030, with a CAGR of 6.80% during the forecast period.

Cited Sources:

1. MedsGo - VENTOLIN Salbutamol 200mcg Rotacap 1's
2. GSK - Responsible Business Supplement 2016
3. Data Bridge Market Research - Global Albuterol Market
4. EPA - Market Characterization of the U.S. Metered Dose Inhaler Industry
5. GSK - GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials